Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To determine the efficacy of TMC435 plus PegIFNalfa-2a and RBV when administered for 12 weeks in treatment-naïve subjects with chronic genotype 1 HCV infection, as measured by the proportion of subjects with sustained virologic response 12 weeks after planned end of treatment (SVR12). - To assess the safety and tolerability of TMC435 plus PegIFNalfa-2a and RBV when administered for 12 weeks in treatment-naïve subjects with the chronic genotype 1 HCV infection
Critère d'inclusion
- Hepatitis C Virus (HCV) genotype-1 infection